Isan Chen
Founder at Mbrace Therapeutics, Inc.
Net worth: 3 M $ as of 2024-06-29
Profile
Isan Chen is the founder of Mbrace Therapeutics, Inc. (founded in 2020) and currently holds the position of President, Chief Executive Officer & Director.
Dr. Chen is also currently working as a Director at Treadwell Therapeutics, Inc. Dr. Chen previously worked as an Independent Director at Tyra Biosciences, Inc. from 2019 to 2024.
From 2004 to 2010, Dr. Chen served as the Vice President-Tumor Strategy at Pfizer Inc. Dr. Chen was the Chief Medical & Development Officer, Executive VP at Mirati Therapeutics, Inc. from 2013 to 2020.
Dr. Chen also held the position of Assistant Professor at The University of Texas M.D.
Anderson Cancer Center.
From 2010 to 2013, Dr. Chen was the Chief Medical Officer at Aragon Pharmaceuticals, Inc. Dr. Chen obtained a doctorate degree from the University of Sao Paulo.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
TYRA BIOSCIENCE, INC
0.37% | 2024-03-25 | 192,783 ( 0.37% ) | 3 M $ | 2024-06-29 |
Isan Chen active positions
| Companies | Position | Start |
|---|---|---|
Mbrace Therapeutics, Inc.
 Mbrace Therapeutics, Inc. BiotechnologyHealth Technology Mbrace Therapeutics, Inc. is an American company that specializes in antibody discovery methodology. The company's approach, called SPARTA, overcomes several challenges to generate human antibodies that can be quickly translated into clinical applications. Mbrace Therapeutics was founded by Renata Pasqualini, Isan Chen, and Wadih Arap, with Isan Chen serving as the CEO since incorporation. | Founder | 2020-04-30 |
Treadwell Therapeutics, Inc.
 Treadwell Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Treadwell Therapeutics, Inc. operates as a clinical-stage oncology firm. It develops small molecules designed to leverage world-class, innovative science in cancer biology and immune-oncology with pan-cancer potential, including hematological malignancies from the TIO Discovery development engine. The company was founded by Tak Wah Mak and Mark R. Bray in July 2019 and is headquartered in New York, NY. | Director/Board Member | - |
Former positions of Isan Chen
| Companies | Position | End |
|---|---|---|
| TYRA BIOSCIENCES, INC. | Director/Board Member | 2024-05-06 |
| MIRATI THERAPEUTICS | Chief Tech/Sci/R&D Officer | 2020-05-17 |
Aragon Pharmaceuticals, Inc.
 Aragon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aragon Pharmaceuticals, Inc. develops biopharmaceutical products, It offers a pipeline of new anti-endocrine therapies targeting the biology of hormone resistant cancers. The company was founded by Charles L. Sawyers and Michael Jung on May 1, 2009 and is headquartered in San Diego, CA. | Chief Tech/Sci/R&D Officer | 2013-06-30 |
| PFIZER, INC. | Corporate Officer/Principal | 2009-12-31 |
The University of Texas M.D. Anderson Cancer Center
 The University of Texas M.D. Anderson Cancer Center Other Consumer ServicesConsumer Services The University of Texas M.D. Anderson Cancer Center provides cancer patient care, research, and prevention for cancer. The firm also provides education for undergraduate and graduate students, trainees, professionals, employees and the publics. The company was founded in 1941 and is headquartered in Houston, TX. | Corporate Officer/Principal | - |
Training of Isan Chen
| University of Sao Paulo | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| PFIZER, INC. | Health Technology |
| TYRA BIOSCIENCES, INC. | Health Technology |
| Private companies | 5 |
|---|---|
Mirati Therapeutics, Inc.
 Mirati Therapeutics, Inc. BiotechnologyHealth Technology Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA. | Health Technology |
Aragon Pharmaceuticals, Inc.
Aragon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aragon Pharmaceuticals, Inc. develops biopharmaceutical products, It offers a pipeline of new anti-endocrine therapies targeting the biology of hormone resistant cancers. The company was founded by Charles L. Sawyers and Michael Jung on May 1, 2009 and is headquartered in San Diego, CA. | Health Technology |
The University of Texas M.D. Anderson Cancer Center
The University of Texas M.D. Anderson Cancer Center Other Consumer ServicesConsumer Services The University of Texas M.D. Anderson Cancer Center provides cancer patient care, research, and prevention for cancer. The firm also provides education for undergraduate and graduate students, trainees, professionals, employees and the publics. The company was founded in 1941 and is headquartered in Houston, TX. | Consumer Services |
Mbrace Therapeutics, Inc.
Mbrace Therapeutics, Inc. BiotechnologyHealth Technology Mbrace Therapeutics, Inc. is an American company that specializes in antibody discovery methodology. The company's approach, called SPARTA, overcomes several challenges to generate human antibodies that can be quickly translated into clinical applications. Mbrace Therapeutics was founded by Renata Pasqualini, Isan Chen, and Wadih Arap, with Isan Chen serving as the CEO since incorporation. | Health Technology |
Treadwell Therapeutics, Inc.
Treadwell Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Treadwell Therapeutics, Inc. operates as a clinical-stage oncology firm. It develops small molecules designed to leverage world-class, innovative science in cancer biology and immune-oncology with pan-cancer potential, including hematological malignancies from the TIO Discovery development engine. The company was founded by Tak Wah Mak and Mark R. Bray in July 2019 and is headquartered in New York, NY. | Health Technology |
- Stock Market
- Insiders
- Isan Chen
